These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 23769056

  • 1. Mouse T cells engineered to display on their surface a novel form of FasL protein undergo apoptosis when stimulated with alloantigens: implications for graft-versus-host disease.
    Yolcu ES, Singh NP.
    Transplant Proc; 2013 Jun; 45(5):1850-2. PubMed ID: 23769056
    [Abstract] [Full Text] [Related]

  • 2. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
    Askenasy N, Mizrahi K, Ash S, Askenasy EM, Yaniv I, Stein J.
    Biol Blood Marrow Transplant; 2013 Feb; 19(2):185-95. PubMed ID: 23078782
    [Abstract] [Full Text] [Related]

  • 3. Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease.
    Shrestha P, Turan A, Batra L, Gulen AE, Sun Z, Tan H, Askenasy N, Shirwan H, Yolcu ES.
    Blood Adv; 2023 May 23; 7(10):2181-2195. PubMed ID: 36780582
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
    Pan Y, Luo B, Sozen H, Kalscheuer H, Blazar BR, Sutherland DE, Hering BJ, Guo Z.
    Transplantation; 2003 Jul 15; 76(1):216-24. PubMed ID: 12865813
    [Abstract] [Full Text] [Related]

  • 10. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
    Davenport C, George T, Devora GA, Morris MA, Gordon BE, Kumar V, Bennett M.
    Biol Blood Marrow Transplant; 1997 Dec 15; 3(6):294-303. PubMed ID: 9502296
    [Abstract] [Full Text] [Related]

  • 11. High expression of Fas ligand on cord blood dendritic cells: a possible immunoregulatory mechanism after cord blood transplantation.
    Naderi N, Moazzeni SM, Pourfathollah AA, Alimoghaddam K.
    Transplant Proc; 2011 Dec 15; 43(10):3913-9. PubMed ID: 22172872
    [Abstract] [Full Text] [Related]

  • 12. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS.
    J Immunol; 1998 Sep 15; 161(6):2848-55. PubMed ID: 9743345
    [Abstract] [Full Text] [Related]

  • 13. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.
    Yolcu ES, Zhao H, Bandura-Morgan L, Lacelle C, Woodward KB, Askenasy N, Shirwan H.
    J Immunol; 2011 Dec 01; 187(11):5901-9. PubMed ID: 22068235
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH.
    J Immunol; 1986 Jan 01; 136(1):28-33. PubMed ID: 2933464
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells.
    Iwasaki T, Hamano T, Saheki K, Kuroiwa T, Kataoka Y, Takemoto Y, Ogata A, Sugihara A, Terada N, Fujimoto J, Kakishita E.
    Cell Immunol; 1999 Oct 10; 197(1):30-8. PubMed ID: 10555993
    [Abstract] [Full Text] [Related]

  • 20. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease.
    Hashimoto D, Asakura S, Matsuoka K, Sakoda Y, Koyama M, Aoyama K, Tanimoto M, Teshima T.
    Eur J Immunol; 2007 Jan 10; 37(1):271-81. PubMed ID: 17154260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.